The History
Two names on the patent: who owned Melanotan, and how it got loose
A gray-market vial of Melanotan II is, in the eyes of intellectual-property law, an orphan. No company owns the molecule inside it. No patent covers it. Nobody collects a royalty when a peptide lab ships another gram. That is a strange fate for a compound that began life as carefully owned university property, with named inventors and a numbered paper trail — and the strangeness is the whole point.
To understand why anyone can legally make Melanotan II but no one can legally sell it for people to inject, you have to follow the patents. They lead somewhere the tanning forums rarely do: to two FDA-approved drugs, an Australian rename, a lawsuit over the leftovers, and the quiet moment a molecule slipped out of private hands into the public domain.
The inventors, on the record
Melanotan has authors — not in the loose sense the internet uses the word, but in the legal one: people whose names sit on issued United States patents, dated and searchable.
The chemistry came out of the University of Arizona, where, as the origin of this whole story records (where Melanotan came from), the chemist Victor J. Hruby and the biologist Mac E. Hadley spent the 1980s building stable analogs of α-MSH. The molecules they made are written into the patent record. US Patent 5,674,839, Cyclic Analogs of Alpha-MSH Fragments, issued in October 1997 to Hruby, Hadley, and their colleague Fahad Al-Obeidi — that is the Melanotan II family. Its companion, US Patent 5,714,576, Linear Analogs of Alpha-MSH Fragments, covers the Melanotan I side. Two further patents in Hadley’s name — one from 1996 on treating erectile dysfunction, one from 2000 on stimulating sexual response in women — staked out the uses the lab’s famous accident had exposed.
Four documents, three named scientists, a decade of filing dates. Whatever else Melanotan II is, it is not anonymous. Everything the gray market sells was first written down, in public, by people who signed their work.
The middleman most buyers never hear about
Universities do not manufacture drugs, and as a rule they do not sell their patents outright. They license them — usually through a technology-transfer intermediary whose whole job is to turn academic IP into commercial products in exchange for royalties. For the Arizona melanocortin portfolio, that intermediary was Competitive Technologies, a Connecticut licensing firm.
This is the part of the story that reframes everything downstream. The University of Arizona never “sold Melanotan.” It handed a portfolio to a licensor, and that licensor could carve the rights up: this use to one company, that use to another. One molecule, licensable in pieces. Which is exactly how it split in two.
The tan fork: a sunscreen idea becomes a rare-disease drug
The first piece went to Melanotan I. Competitive Technologies licensed it to EpiTan, an Australian startup founded in 1999 to develop the peptide as a photoprotective drug. In 2006 EpiTan renamed itself Clinuvel Pharmaceuticals, and under that name it did the slow, expensive, entirely legitimate work the molecule had always needed: real trials, a controlled-release implant, a regulator to answer to.
The destination was not the tanning salon. Clinuvel developed Melanotan I — now called afamelanotide, sold as SCENESSE — for erythropoietic protoporphyria, a rare inherited disorder in which sunlight causes severe pain. Europe approved it in 2014; the US FDA followed in October 2019. The peptide first imagined as sunscreen for whole populations reached the market as an orphan drug for a few thousand patients. It got there properly, and it stayed owned every step of the way.
The arousal fork: a side effect becomes a franchise
The second piece followed the accident. Around 2000, Palatin Technologies licensed the sexual-dysfunction rights that traced back to Melanotan II — then promptly stopped developing MT-II itself and engineered a close relative, bremelanotide, tuned toward the brain receptors and away from the skin. Bremelanotide became Vyleesi, FDA-approved in June 2019 for hypoactive sexual desire disorder in premenopausal women. That pivot has its own chapter (the eight-hour afternoon that started it); what matters here is the ownership. Even the leftovers were litigated: Competitive Technologies and Palatin fought over the rights and settled in 2008, with Palatin keeping bremelanotide, handing Melanotan II back, and paying $800,000. Two companies in court over a molecule one of them had already walked away from.
Both licensed forks, note, ended the same way — in a branded, patented, regulator-approved product. Neither of them was a tan you could buy.
How the molecule slipped its leash
So where does the gray-market vial come from, if both licensed paths led to prescription drugs?
From the gap between the products and the molecule. Afamelanotide and bremelanotide are protected: distinct compounds, branded, wrapped in their own later patents and regulatory exclusivities. But Melanotan II itself — the exact peptide dissolved in those vials — was never any of those things. Its structure was published in peer-reviewed chemistry in the late 1980s and laid out, in full, in the issued patents; public disclosure is what a patent is. And a US patent is a twenty-year lease, not a deed. The foundational claims covering the molecule were filed in the early 1990s and have long since expired.
Put those two facts together and the gray market stops being mysterious. Synthesizing Melanotan II today infringes no one’s patent, because there is no patent left to infringe and the recipe was public from the start. The molecule is, in the plainest sense, in the public domain.
What remains illegal is selling it for people to inject — and that prohibition comes from an entirely different body of law. Medicines regulators (the FDA, the UK’s MHRA, Australia’s TGA) control what may be marketed for human use, and none of them has approved Melanotan II for anything (the three doors walks through why). It is the distinction almost every buyer misses: the gray market is not pirating a patent. It is making a public-domain compound and skipping the regulator.
What the paper trail shows
Trace all four patents to their ends and a single shape emerges. One university portfolio produced two approved drugs, both landing in 2019, for a rare porphyria and a desire disorder — and not one milligram of approved medicine for the durable, population-wide sunscreen the work set out to build. The pieces that got developed properly are owned, named, and regulated. The piece the public actually injects is owned by nobody, known only by a lab code, and regulated only in the breach.
The tan, in the end, was the one thing no company could figure out how to own. So it became the one thing that got away.